Second-Generation Antipsychotics and Dysregulation of Glucose Metabolism: Beyond Weight Gain
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Second-generation antipsychotics (SGAs) are the cornerstone of treatment for schizophrenia because of their high clinical efficacy. However, SGA treatment is associated with severe metabolic alterations and body weight gain, which can increase the risk of type 2 diabetes and cardiovascular disease, and greatly accelerate mortality. Several underlying mechanisms have been proposed for antipsychotic-induced weight gain (AIWG), but some studies suggest that metabolic changes in insulin-sensitive tissues can be triggered before the onset of AIWG. In this review, we give an outlook on current research about the metabolic disturbances provoked by SGAs, with a particular focus on whole-body glucose homeostasis disturbances induced independently of AIWG, lipid dysregulation or adipose tissue disturbances. Specifically, we discuss the mechanistic insights gleamed from cellular and preclinical animal studies that have reported on the impact of SGAs on insulin signaling, endogenous glucose production, glucose uptake and insulin secretion in the liver, skeletal muscle and the endocrine pancreas. Finally, we discuss some of the genetic and epigenetic changes that might explain the different susceptibilities of SGA-treated patients to the metabolic side-effects of antipsychotics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Correll, C. U., Solmi, M., Veronese, N., Bortolato, B., Rosson, S., Santonastaso, P., Thapa‐Chhetri, N., Fornaro, M., Gallicchio, D., Collantoni, E., et al. (2017) · World Psychiatry · doi:10.1002/wps.20420 · Cited by 1,729
Correll, C. U. (2009) · JAMA · doi:10.1001/jama.2009.1549 · Cited by 1,050 · cited 2×
“In fact, is well known that the pediatric population is especially susceptible to the metabolic side-effects of SGAs [38,39].”
BackgroundMiyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988 · cited 1×
“In contrast to the exclusively high affinity binding of FGAs to D2R, SGAs exert their action by engaging with a broader range of receptors, including dopamine (D1R, D2R and D4R), serotonin (5-HT1A, 5-HT2A, 5-HT2C, 5-HT6, 5-HT7), histamine (H1R) and muscarinic (M3R) receptors [15,16].”
BackgroundExcess mortality of schizophrenia: A meta-analysis
Brown, S. (1997) · British Journal of Psychiatry · doi:10.1192/bjp.171.6.502 · Cited by 869
Regulation of glucose metabolism from a liver-centric perspective
Han, H.-S., Kang, G., Kim, J. S., Choi, B. H., & Koo, S.-H. (2016) · Experimental & Molecular Medicine · doi:10.1038/emm.2015.122 · Cited by 835
Vancampfort, D., Correll, C. U., Galling, B., Probst, M., De Hert, M., Ward, P. B., Rosenbaum, S., Gaughran, F., Lally, J., & Stubbs, B. (2016) · World Psychiatry · doi:10.1002/wps.20309 · Cited by 659
Mortality gap for people with bipolar disorder and schizophrenia: UK-based cohort study 2000–2014
Hayes, J. F., Marston, L., Walters, K., King, M. B., & Osborn, D. P. J. (2017) · British Journal of Psychiatry · doi:10.1192/bjp.bp.117.202606 · Cited by 451
Third Generation Antipsychotic Drugs: Partial Agonism or Receptor Functional Selectivity?
Mailman, R., & Murthy, V. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210790361461 · Cited by 311
Larsen, J. R., Vedtofte, L., Jakobsen, M. S. L., Jespersen, H. R., Jakobsen, M. I., Svensson, C. K., Koyuncu, K., Schjerning, O., Oturai, P. S., Kjaer, A., et al. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.1220 · Cited by 250
Clinical pharmacology of atypical antipsychotics: an update
Mauri, M. C., Paletta, S., Maffini, M., Colasanti, A., Dragogna, F., Di Pace, C., & Altamura, A. C. (2014) · Technische Universität Dortmund · doi:10.17877/de290r-7037 · Cited by 250 · cited 1×
“In contrast to the exclusively high affinity binding of FGAs to D2R, SGAs exert their action by engaging with a broader range of receptors, including dopamine (D1R, D2R and D4R), serotonin (5-HT1A, 5-HT2A, 5-HT2C, 5-HT6, 5-HT7), histamine (H1R) and muscarinic (M3R) receptors [15,16].”
BackgroundFifty years chlorpromazine: a historical perspective
Ban, T. A. (2007) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.a922 · Cited by 227
Sykes, D. A., Moore, H., Stott, L., Holliday, N., Javitch, J. A., Lane, J. R., & Charlton, S. J. (2017) · Nature Communications · doi:10.1038/s41467-017-00716-z · Cited by 218
Nielsen, J., Skadhede, S., & Correll, C. U. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.78 · Cited by 207
Teff, K. L., Rickels, M. R., Grudziak, J., Fuller, C., Nguyen, H.-L., & Rickels, K. (2013) · Diabetes · doi:10.2337/db13-0430 · Cited by 195 · cited 3×
“In another study in healthy subjects without psychiatric history and with normal body-mass index, olanzapine or aripiprazole (10 mg/d) were administered for 9 days and insulin sensitivity was evaluated after conducting a meal challenge before and after HEC analysis [49].”
BackgroundMethodSiskind, D., Hahn, M., Correll, C. U., Fink‐Jensen, A., Russell, A. W., Bak, N., Broberg, B. V., Larsen, J., Ishøy, P. L., Vilsbøll, T., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13522 · Cited by 144
Rajkumar, A. P., Horsdal, H. T., Wimberley, T., Cohen, D., Mors, O., Børglum, A. D., & Gasse, C. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16040442 · Cited by 137
Atypical Antipsychotics Alter Cholesterol and Fatty Acid Metabolism in Vitro
Canfrán-Duque, A., Casado, M. E., Pastor, Ó., Sánchez-Wandelmer, J., de la Peña, G., Lerma, M., Mariscal, P., Bracher, F., Lasunción, M. A., & Busto, R. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m026948 · Cited by 105 · cited 1×
“On the other hand, increased cholesterol levels could be due to a direct effect of SGAs in lipid metabolism independently of changes in glucose metabolism, as these drugs up-regulate sterol regulatory element binding protein-2 (SREBP-2) [60,61], the master regulator of cholesterol biosynthesis.”
BackgroundShi, S., Leites, C., He, D., Schwartz, D., Moy, W., Shi, J., & Duan, J. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.535203 · Cited by 61
Yilmaz, Z., Zai, C. C., Hwang, R., Mann, S., Arenovich, T., Remington, G., & Daskalakis, Z. J. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.06.027 · Cited by 52
Brain stem as a target site for the metabolic side effects of olanzapine
Anwar, I. J., Miyata, K., & Zsombok, A. (2016) · Journal of Neurophysiology · doi:10.1152/jn.00387.2015 · Cited by 13
Cited by
The Burden of Antipsychotic-Induced Weight Gain and Metabolic Syndrome in Children
Libowitz, M. R., & Nurmi, E. L. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.623681 · Cited by 99
Garcia-Argibay, M., Li, L., Du Rietz, E., Zhang, L., Yao, H., Jendle, J., Ramos-Quiroga, J. A., Ribasés, M., Chang, Z., Brikell, I., et al. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105076 · Cited by 52
“…factors such as overweight and obesity, sedentary behaviors, poor dietary habits, smoking, hypertension, sleeping disorders, depression, antipsychotics use and non-modifiable factors such as age, family history of T2D, and history of gestational diabetes (Chen et al., 2012; Grajales et al., 2019).”
Reversibility of Antipsychotic-Induced Weight Gain: A Systematic Review and Meta-Analysis
Speyer, H., Westergaard, C., Albert, N., Karlsen, M., Stürup, A. E., Nordentoft, M., & Krogh, J. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.577919 · Cited by 44
Metadata
- Authors
- Grajales, D., Ferreira, V., & Valverde, Á. M.
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2019-10-29
- Volume
- 8
- Issue
- 11
- Pages
- 1336
- ISSN
- 2073-4409 (ISSN-L)
- OpenAlex
- W2982423055
- Cited by
- 179
- References
- 20
- FWCI
- 11.95
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.